Optimization of guideline-directed medical therapies in patients with diabetes and chronic kidney disease.
糖尿病和慢性腎臟病患者指導方針下藥物治療的優化。
Clin Kidney J 2024-01-13
Impact of Dapagliflozin Adjunctive Therapy on the Progression of Chronic Kidney Disease in Patients with Type 2 Diabetes and Chronic Kidney Disease Stages 2-5: A systematic review and meta-analysis.
Dapagliflozin 輔助療法對於 2 型糖尿病及慢性腎病 2-5 期患者慢性腎病進展的影響:系統性回顧與統合分析。
Sultan Qaboos Univ Med J 2024-09-05
Summary of Research: Dapagliflozin Utilization in Chronic Kidney Disease and Its Real-World Effectiveness Among Patients with Lower Levels of Albuminuria in the USA and Japan.
研究摘要:Dapagliflozin 在慢性腎病中的應用及其在美國和日本低白蛋白尿患者中的實際效果。
Adv Ther 2024-09-19
Trends in Antidiabetic Drug Use and Safety of Metformin in Diabetic Patients with Varying Degrees of Chronic Kidney Disease from 2010 to 2021 in Korea: Retrospective Cohort Study Using the Common Data Model.
2010年至2021年韓國糖尿病患者中不同程度慢性腎病的抗糖尿病藥物使用趨勢及Metformin的安全性:使用共同數據模型的回顧性隊列研究。
Pharmaceuticals (Basel) 2024-10-26
Optimizing Prescribing for Individuals With Type 2 Diabetes and Chronic Kidney Disease Through the Development and Validation of Algorithms for Community Pharmacists.
透過為社區藥師開發和驗證算法,優化對2型糖尿病和慢性腎病患者的處方。
Can J Kidney Health Dis 2025-01-21
The impact of metformin on kidney disease progression and mortality in diabetic patients using SGLT2 inhibitors: a real-world cohort study.
使用 SGLT2 抑制劑的糖尿病患者中,metformin 對腎病進展和死亡率的影響:一項真實世界的隊列研究。
Cardiovasc Diabetol 2025-02-28
這項回顧性研究分析了2016至2021年間Clalit Health Services的數據,評估2型糖尿病成人中,metformin與SGLT2抑制劑聯合使用的效果。研究納入45,545名患者,經過匹配後每組有6,774名。結果顯示,聯合療法顯著降低全因死亡率(風險比0.74)及腎病進展風險(風險比0.65),且住院、急性腎損傷及代謝性酸中毒的風險也較低。研究支持將此聯合療法作為2型糖尿病的一線治療策略,對減少腎病進展及死亡率有明顯益處。
PubMedDOI
Pharmacokinetic Properties of Dapagliflozin in Patients with Stage 4 Chronic Kidney Disease.
第四期慢性腎病患者中Dapagliflozin的藥物動力學特性。
Am J Nephrol 2025-03-16
Dapagliflozin in Chronic Kidney Disease: Insights from Network Pharmacology and Molecular Docking Simulation.
慢性腎病中的 Dapagliflozin:來自網絡藥理學和分子對接模擬的見解。
Life (Basel) 2025-03-27